Singapore-based ASLAN Pharmaceuticals has signed an understanding with the National Cancer Centre of Singapore (NCCS) to study novel combination therapies to treat gastric cancer, hepatocellular carcinoma and cholangiocarcinoma, in its second move in this month to explore wider avenues for its existing clinical trial candidates.
After scoring FDA approval last week for its finger-stick herpes test and striking its first deal to provide its tests for a private insurer, Theranos is teaming up with a managed care provider to offer its tests to Medicaid patients and snagging a CLIA waiver from the FDA for its herpes testing system.
Five Prime Therapeutics is buying to Inhibrx's early-stage cancer R&D, signing a deal worth up to $452.5 million to get its hands on an immuno-oncology project.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Theranos has major ambitions--and, if you glance at the composition of its board, it's obvious that diagnostics cost-savings on the massive scale of the U.S. government is at the core of them. Now, it's made a first partnership that moves it toward realizing that goal. It will offer diagnostic testing through managed care provider AmeriHealth Caritas, which serves more than 6.6 million patients across 16 states and the District of Columbia--the bulk of whom are on Medicaid.
The Merck Global Health Innovation Fund invested $6 million in OpGen on the same day the microbial genetics specialist announced it will acquire AdvanDx, a maker of molecular tests for blood cultures.
Four partners have gotten together in the hopes of developing technology to replace traditional glucometers--and maybe even manage insulin delivery with smartphone-based systems. Wearables specialist Gentag and the Mayo Clinic are expanding upon their ongoing collaboration and adding into the mix a pair of existing partners: sensor maker NovioSense and the Fraunhofer Institute for Microelectronic Circuits and Systems (IMS).
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.
Sanofi has widened its R&D net, recruiting 7 of the U.S.'s most-respected research institutions in hopes of ferreting out some new ideas in early-stage drug development.
The National Basketball Association and GE Healthcare have signed a multiyear deal to work together to advance the prevention, diagnosis and treatment of musculoskeletal conditions among NBA players.